REMDESIVIR PRICING WAR HOTS UP
Sep 06, 2020
4 minutes
VUYO MKIZE vuyo.mkize@citypress.co.za
As the dispute about the pricing of remdesivir – a potential Covid-19 antiviral drug – intensifies, with heated arguments regarding access to and pricing of medicines and medical interventions during a pandemic, at least one more generic pharmaceutical company has entered the fray.
This week, Indian generic pharmaceutical company Hetero, one of the world’s largest producers of antiretroviral drugs, followed Cipla SA (also a pharmaceutical manufacturer focused on generics) by distributing the drug to South Africa’s private healthcare sector.
The drug – which was found to reduce the recovery time of patients hospitalised for Covid-19 and needing supplementary oxygen therapy from
You’re reading a preview, subscribe to read more.
Start your free 30 days